STOCK TITAN

Emergent Biosolutions Stock Price, News & Analysis

EBS NYSE

Company Description

Overview and Core Mission

Emergent BioSolutions Inc (EBS) is a global life sciences enterprise dedicated to protecting and enhancing lives by developing, manufacturing, and delivering a broad portfolio of medical countermeasures. With a commitment to public health preparedness, this company addresses complex challenges in biodefense and emerging infectious diseases by offering advanced vaccines, therapeutics, and integrated development services. Operating at the intersection of innovation and critical public health needs, Emergent employs state-of-the-art research and manufacturing practices to provide reliable solutions that keep populations safe from potential biological and chemical threats.

Business Segments and Operational Excellence

The company’s operations are organized across three primary segments: Commercial, Products, and Services. The Commercial segment, which includes flagship products such as NARCAN, plays a pivotal role in generating revenue by offering life-saving therapies to government agencies and healthcare providers. Meanwhile, the Products and Services segments focus on the development and manufacturing of complex vaccines and therapeutics that target critical infectious and chemical threats. With a diversified business model that spans contract manufacturing, vaccine production, and countermeasure services, Emergent BioSolutions has established itself as a trusted partner in both governmental biodefense strategies and public health emergency responses.

Market Position and Industry Relevance

Emergent BioSolutions is uniquely positioned within the life sciences industry due to its comprehensive product portfolio and its long-standing relationships with key public sector clients. The company’s strategic engagements with federal agencies, including collaborations and contracts with BARDA and other initiatives focused on addressing smallpox, mpox, Ebola, anthrax, and opioid overdose emergencies, highlight its central role in ensuring national and global health security. Its operational capabilities, coupled with a continuous drive for process optimization and technology adoption, provide a competitive edge in a market where readiness and rapid response are paramount.

Expertise in Government and Healthcare Collaboration

At the heart of Emergent's enterprise is a deep commitment to public health and biodefense, reinforced by robust government and industry partnerships. By consistently delivering critical medical countermeasures, the company serves as a vital resource for emergency preparedness. Its collaborations extend across federal agencies, international health organizations, and academic institutions, ensuring that its products meet rigorous regulatory and safety standards. This integrated approach not only enhances its credibility but also supports large-scale deployment of life-saving treatments during public health crises.

Scientific Rigor and Manufacturing Prowess

Emergent BioSolutions excels in utilizing advanced scientific methodologies and high-quality manufacturing standards. Research-driven innovation underpins every phase of its operations, from initial development to large-scale production. The company employs a highly specialized workforce and state-of-the-art technology to navigate complex regulatory landscapes and ensure product efficacy and safety. The result is a robust portfolio that includes vaccines and therapeutics designed to defend against catastrophic biological incidents, chemical threats, and widespread infectious diseases.

Operational Integrity and Industry Leadership

While firmly rooted in its core mission of protecting life, Emergent BioSolutions embraces a model of operational integrity and dynamic responsiveness. Its decentralized execution model across multiple segments allows for agility in responding to urgent public health threats. Moreover, the company’s ability to secure substantial government contracts and form strategic financing arrangements underscores its stability and agility within a challenging market environment. This operational strength is a testament to its nuanced approach to managing risk, regulatory compliance, and continuous process improvement.

Commitment to Quality and Regulatory Excellence

The company’s priority of safety and quality is evident throughout its practices and product lines. Rigorous compliance with local and international regulatory standards ensures that every vaccine, therapeutic, and service offering is designed for reliability and effectiveness. Through meticulous product validation, process control, and continuous quality improvement, Emergent BioSolutions maintains high-authority status in public health preparedness and biodefense sectors. The company exemplifies the integration of scientific expertise with practical manufacturing solutions, reinforcing its role as an essential provider of critical countermeasures.

Conclusion

Emergent BioSolutions Inc represents a confluence of scientific advancement, operational excellence, and strategic governmental collaboration. Its expansive and diversified product portfolio, together with a proven track record in addressing public health emergencies, positions it as a significant entity within the global life sciences industry. As healthcare challenges evolve, the company remains a steadfast guardian of public health, driven by an unwavering mission to protect and enhance life through innovative solutions and strategic partnerships.

Stock Performance

$—
0.00%
0.00
Last updated:
269.11 %
Performance 1 year
$269.8M
Market Cap
54.3M
Shares outstanding

SEC Filings

No SEC filings available for Emergent Biosolutions.

Financial Highlights

$1,043,600,000
Revenue (TTM)
-$190,600,000
Net Income (TTM)
-$3.60
Diluted EPS (TTM)
$58,700,000
Operating Cash Flow
-18.26%
Net Profit Margin
-10.42%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Emergent Biosolutions (EBS)?

The current stock price of Emergent Biosolutions (EBS) is $5.37 as of April 24, 2025.

What is the market cap of Emergent Biosolutions (EBS)?

The market cap of Emergent Biosolutions (EBS) is approximately 269.8M.

What is the revenue (TTM) of Emergent Biosolutions (EBS) stock?

The trailing twelve months (TTM) revenue of Emergent Biosolutions (EBS) is $1,043,600,000.

What is the net income of Emergent Biosolutions (EBS)?

The trailing twelve months (TTM) net income of Emergent Biosolutions (EBS) is -$190,600,000.

What is the earnings per share (EPS) of Emergent Biosolutions (EBS)?

The diluted earnings per share (EPS) of Emergent Biosolutions (EBS) is -$3.60 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Emergent Biosolutions (EBS)?

The operating cash flow of Emergent Biosolutions (EBS) is $58,700,000.

What is the profit margin of Emergent Biosolutions (EBS)?

The net profit margin of Emergent Biosolutions (EBS) is -18.26%.

What is the operating margin of Emergent Biosolutions (EBS)?

The operating profit margin of Emergent Biosolutions (EBS) is -10.42%.

What is the current ratio of Emergent Biosolutions (EBS)?

The current ratio of Emergent Biosolutions (EBS) is 3.69, indicating the company's ability to pay short-term obligations.

What is the operating income of Emergent Biosolutions (EBS)?

The operating income of Emergent Biosolutions (EBS) is -$108,700,000.

What is the primary mission of Emergent BioSolutions?

Emergent BioSolutions is dedicated to protecting and enhancing life by developing, manufacturing, and delivering medical countermeasures to address public health threats and biodefense challenges.

How does Emergent BioSolutions generate its revenue?

The company generates revenue through its three business segments—Commercial, Products, and Services—with its commercial segment playing a major role by supplying essential products and therapeutics to government and healthcare providers.

What types of products does Emergent BioSolutions offer?

Emergent’s portfolio includes innovative vaccines, therapeutics, and treatments designed to counteract chemical, biological, and infectious threats, as well as integrated contract development and manufacturing services.

How does the company support public health and emergency preparedness?

Through strategic partnerships with government agencies and public health organizations, Emergent develops and supplies critical countermeasures that are integral for biodefense and preparedness against public health emergencies.

What are the main business segments of Emergent BioSolutions?

Emergent operates across three main segments: Commercial, which includes high-impact products; Products, focusing on vaccine and therapeutic development; and Services, which provide integrated manufacturing and development support.

In which industries does Emergent operate?

The company operates within the life sciences, pharmaceutical, biodefense, and public health sectors, with a special focus on developing solutions for countering infectious diseases as well as chemical and biological threats.

How does Emergent BioSolutions ensure the safety and efficacy of its products?

Emergent employs advanced scientific research, rigorous manufacturing standards, and strict adherence to regulatory compliance, ensuring its products meet high standards of safety, quality, and effectiveness.

What role do government contracts play in Emergent's business model?

Government contracts are vital components of Emergent’s operations, enabling the company to secure substantial orders and partnerships that support the development and distribution of critical public health countermeasures.